AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8164297
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of fiber (control)
Trial: 28528342
Drug: Nutricosmeceutical containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutricosmeceutical containing collagen bioactive peptides and antioxidants (50 mL daily)
Trial: 28528342
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mL daily)
Trial: 23220477
Drug: Acetaminophen (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4.0 g/day; n = 11)
Trial: 23220477
Drug: Ibuprofen (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1.2 g/day; n = 13)
Trial: 25090744
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.6 mg/kg alone
Trial: 25090744
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.6 mg/kg with nitrous oxide-oxygen inhalation
Trial: 9398709
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with insulin
Trial: 9100593
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy alone
Trial: 2890951
Drug: Dipyridamole 75
RxNorm normalized name: dipyridamole 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP‐ASA)
Trial: 24957485
Drug: high-dose casein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose casein (HP) 51.7 kcal
Trial: 24957485
Drug: high-dose sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-dose sucrose (HC) 51.7 kcal
Trial: 24957485
Drug: low-dose casein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose casein (LP) 17.2 kcal
Trial: 24957485
Drug: low-dose sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose sucrose (LC) 17.2 kcal
Trial: 24112417
Drug: 14-week intensive
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-week intensive intervention including breastfeeding benefits, understanding GDM, nutrition and exercise education, coping skills training, physical activity, educational and motivational text messaging, and 3 months of continued monthly contact
Trial: 17980497
Drug: Gonadotropin Releasing
RxNorm normalized name: Gonadotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin Releasing Hormone analogue (GnRHa) treatment
Trial: 15073842
Drug: Irinotecan and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan and oxaliplatin in combination with infusional 5‐FU/LV
Trial: 11842947
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special therapy
Trial: 20394254
Drug: Dextromethorphan 90
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 90 mg
Trial: 8094308
Drug: Granulocyte-macrophage colony
RxNorm normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony stimulating factor (GM-CSF) at a starting dose of 250 micrograms/m2/day as continuous infusion via the IVC catheter.
Trial: 8094308
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg daily) given to both groups.
Trial: 8094308
Drug: Mechanical clot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical clot aspiration used for occlusions during GM-CSF therapy.
Trial: 3666667
Drug: Pirenzepine 2
RxNorm normalized name: pirenzepine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 2 X 25 mg
Trial: 3666667
Drug: Pirenzepine 2
RxNorm normalized name: pirenzepine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 2 X 50 mg
Trial: 10609068
Drug: Single DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single DMARD (methotrexate 7.5‐15 mg/week or sulfasalazine 1‐2 g/day or hydroxychloroquine 200 mg/day)
Trial: 10609068
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MTX + SSZ or MTX + HCQ
Trial: 10609068
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MTX + SSZ + HCQ
Trial: 7492036
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of IM ketorolac and oral placebo
Trial: 7492036
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral indomethacin and IM placebo
Trial: 15611975
Drug: Paclitaxel 70
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 70 mg/m² on Days 1 and 8, carboplatin AUC 5 on Day 1, gemcitabine 1000 mg/m² on Days 1 and 8 every 21 days for a maximum of 8 cycles
Trial: 9681077
Drug: CAPOMEt (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOMEt (weekly regimen incorporating cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and etoposide)
Trial: 7999849
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with rifampin and bacitracin
Trial: 30301241
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (450 mL; 2 kcal)
Trial: 30301241
Drug: M280 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat; 280 kcal)
Trial: 30301241
Drug: M504 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat; 504 kcal)
Trial: 30301241
Drug: P280 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P280 (70 g protein, 0 g carbohydrate, 0 g fat; 280 kcal)
Trial: 28177172
Drug: VIBRANT capsule
RxNorm normalized name: VIBRANT Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIBRANT capsule treatment for 8 weeks
Trial: 28177172
Drug: Sham capsule
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham capsule treatment for 8 weeks
Trial: 28177172
Drug: VIBRANT capsule
RxNorm normalized name: VIBRANT Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIBRANT capsule treatment
Trial: 28177172
Drug: Sham capsule
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham capsule treatment
Trial: 19031710
Drug: Colon purification
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon purification treatment
Trial: 19031710
Drug: Routine anti‐coma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine anti‐coma hepaticum treatments
Trial: 12420730
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous metronidazole 500 mg preoperatively
Trial: 16362397
Drug: Broad-spectrum multi-drug
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum multi-drug regimen (cefuroxime 1.5 g i.v. and metronidazole 0.5 g i.v. preoperatively, co-amoxiclav 375 mg orally 8-hourly postoperatively for 5 days)
Trial: 12921453
Drug: Cephalexin twice
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin twice daily
Trial: 12921453
Drug: Cephalexin three
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin three times daily
Trial: 3243093
Drug: Cefadroxil once
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil once daily
Trial: 11029359
Drug: Thoracoscopic talc
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thoracoscopic talc poudrage (5 g) under local anesthesia
Trial: 2580156
Drug: RO 13‐6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13‐6438 10 mg intravenously
Trial: 2580156
Drug: RO 13‐6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13‐6438 20 mg intravenously
Trial: 2580156
Drug: RO 13‐6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13‐6438 20 mg orally
Trial: 2580156
Drug: RO 13‐6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13‐6438 40 mg orally
Trial: 2580156
Drug: RO 13‐6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13‐6438 60 mg orally
Trial: 31839089
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: periarticular injection of compound analgesics of ropivacaine, ketorolac, adrenaline, morphine and normal saline
Trial: 31839089
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: periarticular injection of compound analgesics of bupivacaine, methylprednisolone, adrenaline, morphine and normal saline
Trial: 24838902
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure therapy (10 cmH2O)
Trial: 20413372
Drug: Calcipotriol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol plus betamethasone dipropionate gel
Trial: 20413372
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate (single component in gel vehicle)
Trial: 20413372
Drug: Calcipotriol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (single component in gel vehicle)
Trial: 17980928
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine with or without OADs
Trial: 17980928
Drug: Prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prandial insulin (once-daily, twice-daily, or more than twice-daily)
Trial: 10081632
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg, 20 mg on days 0 and 4)
Trial: 18768040
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (group A)
Trial: 2127562
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (50 mg 3-times daily)
Trial: 380913
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg once daily)
Trial: 394280
Drug: Diclofenac (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (25 mg, three times daily for the first week, then four or six tablets in the second week)
Trial: 27628045
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 60,000 units 4 weekly (group 1)
Trial: 27628045
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 60,000 units 8 weekly (group 2)
Trial: 15154938
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 2 g/day for 4 weeks
Trial: 12057137
Drug: Radiation given
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy
Trial: 8490338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adenoidectomy and ventilation tubes
Trial: 3688382
Drug: Vidisic (jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidisic (jelly artificial tear solution)
Trial: 3688382
Drug: Dexpanthenol ointment
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol ointment
Trial: 20855114
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg RBZ at baseline and months 1, 3, and 5 (group 1)
Trial: 20855114
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5 mg RBZ and focal or grid laser at baseline and month 3 (group 3)
Trial: 18668535
Drug: rilonacept (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilonacept (160 mg weekly subcutaneous injections)
Trial: 12008860
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride (Prozac)
Trial: 10360845
Drug: Propofol bolus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol bolus dose of 2 mg/kg or 1 mg/kg for those older than 65 years, followed by infusion of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1) of propofol.
Trial: 1778191
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release verapamil (SRV) 360 mg
Trial: 24512053
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg once daily for 52 weeks
Trial: 24512053
Drug: Tofogliflozin 40
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 40 mg once daily for 52 weeks
Trial: 24512053
Drug: Tofogliflozin (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofogliflozin (doses not specified) in add-on trial
Trial: 23216439
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use treatment for AAPIs
Trial: 23216439
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use treatment for non-AAPIs (control group)
Trial: 19081092
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g L-arginine added to a fatty meal (3 ml cream/kg body weight)
Trial: 19081092
Drug: Fatty meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty meal without L-arginine
Trial: 19081092
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g phenylalanine added to a fatty meal
Trial: 19081092
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g leucine added to a fatty meal
Trial: 19081092
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g L-arginine alone (without cream)
Trial: 3067950
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control using ultralente insulin as basal cover and soluble insulin at mealtimes
Trial: 29329551
Drug: Miniscalpel acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miniscalpel acupuncture treatment
Trial: 29329551
Drug: NSAIDs (zaltoprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (zaltoprofen, one oral tablet, three times a day for three weeks)
Trial: 29329551
Drug: Miniscalpel acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miniscalpel acupuncture treatment combined with NSAIDs
Trial: 12557836
Drug: Chloroquine (CQ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ; 25 mg/kg)
Trial: 12557836
Drug: Sulfadoxine-pyrimethamine (SP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP; 25 mg/kg of the sulfadoxine component)
Trial: 12557836
Drug: Mefloquine (MQ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (MQ; 15 mg/kg)
Trial: 1757038
Drug: Methylprednisolone (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (initially 100 mg daily, reduction every 3 days)
Trial: 1757038
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 (100 mg thiamin daily)
Trial: 7041939
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CMF)
Trial: 6146861
Drug: CMF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF treatment
Trial: 30655568
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice daily for 2 weeks
Trial: 30899947
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser combined with basic periodontal therapy
Trial: 30899947
Drug: Basic periodontal
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic periodontal therapy
Trial: 27593618
Drug: NO3‐ rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3‐ rich beetroot juice (4000 mg/L NO3‐)
Trial: 22866961
Drug: Hypocaloric diets
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diets containing different levels of sucrose or high fructose corn syrup (HFCS)
Trial: 20354448
Drug: Hourly urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly urine output (HUO, n = 15)
Trial: 15494721
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pegylated liposomal doxorubicin (PLD) 45 mg m(‐2) and paclitaxel 150 mg m(‐2), every 28 days for a total of six cycles
Trial: 355585
Drug: MPA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (20 mg orally q 8 hr for 32 hr)
Trial: 31356678
Drug: Ketoconazole (KTZ)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KTZ) 200 or 400 mg
Trial: 31451521
Drug: Intermittent low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermittent low-dose ASA (81 mg daily for one week/placebo for one week)
Trial: 31451521
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose ASA (81 mg daily)
Trial: 31451521
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (both intermittent and continuous)
Trial: 26187121
Drug: Radically Open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radically Open Dialectical Behaviour Therapy (RO-DBT) for 7 months (individual and group treatment)
Trial: 21500490
Drug: vitaprost plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitaprost plus in rectal suppositoria for 1 month, then vitaprost forte for 2 months
Trial: 11335733
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/kg/d in 3 daily doses)
Trial: 11335733
Drug: Amoxicillin-clavulanate (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (amoxicillin 45 mg/kg/d in 2 daily doses)
Trial: 7871042
Drug: Caffeine 600
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 600 mg/70 kg
Trial: 29584462
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg caffeine)
Trial: 8781869
Drug: Caffeine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (all doses)
Trial: 2876879
Drug: Haloperidol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (20 mg i.m. on the first day and 20 mg p.o. daily from day 2 to 21)
Trial: 2876879
Drug: Pipothiazine palmitate
RxNorm normalized name: Pipothiazine palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipothiazine palmitate (100 mg i.m. on the first day and daily glass of milk with grenadine from day 2 to 21)
Trial: 29798296
Drug: Weisu granules
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weisu granules combined with Lanqin oral solution
Trial: 29798296
Drug: Lanqin oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanqin oral solution
Trial: 29798296
Drug: Esomeprazole Magnesium
RxNorm normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole Magnesium Enteric-coated Tablets and Lanqin oral solution
Trial: 25498565
Drug: More rigorous
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More rigorous dose calculation algorithm (DCA)
Trial: 25498565
Drug: Laxative as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative as a method of bowel preparation